A controlled family study of cannabis users with and without psychosis.
A controlled family study of cannabis users with and without psychosis.
复制标题
对患有和不患有精神病的大麻使用者进行的对照家庭研究。
DOI：
10.1016/j.schres.2013.11.014
复制
发表时间：
2014
影响因子：
4.5
通讯作者：
Delisi,LynnE
中科院分区：
文献类型：
--
作者：
Proal,AshleyC;Fleming,Jerry;Galvez-Buccollini,JuanA;Delisi,LynnE
背景大麻是世界上滥用最严重的非法药物之一。一些研究表明青少年使用大麻与精神分裂症之间存在联系。了解这种联系将对大麻合法化及其药用价值产生重大影响。本研究旨在确定精神分裂症的家族性发病风险是否是导致青少年大麻使用与精神分裂症发展相关的关键因素。MethodsConstructively获得的先证者被招募到四个样本中：样本1：87名无药物使用的非精神病对照;样本2：84名使用大麻的非精神病对照;样本3：32例无药物使用的精神分裂症谱系精神病患者;样本4：76例使用大麻的精神分裂症谱系精神病患者。所有使用大麻的受试者在青春期使用这种药物，除酒精外，没有其他物质。结构化的先证者和家庭知情人的访谈，以获得先证者和他们所有已知的relatives.ResultsThere的诊断信息，精神分裂症的发病风险增加的亲属的大麻使用和非使用患者的样本相比，他们各自的非精神病对照样本（p = .002，p < .001分别）。精神分裂症的发病风险之间没有显着差异的患者亲属谁使用或不使用大麻（p = .43）。ConclusionsThe结果目前的研究表明，精神分裂症的家族发病风险增加可能是精神分裂症的基础大麻用户，而不是大麻本身的使用。
BackgroundCannabis is one of the most highly abused illicit drugs in the world. Several studies suggest a link between adolescent cannabis use and schizophrenia. An understanding of this link would have significant implications for legalization of cannabis and its medicinal value. The present study aims to determine whether familial morbid risk for schizophrenia is the crucial factor that underlies the association of adolescent cannabis use with the development of schizophrenia.MethodsConsecutively obtained probands were recruited into four samples: sample 1: 87 non-psychotic controls with no drug use; sample 2: 84 non-psychotic controls with cannabis use; sample 3: 32 patients with a schizophrenia spectrum psychosis with no drug use; sample 4: 76 patients with schizophrenia spectrum psychosis with cannabis use. All cannabis using subjects used this drug during adolescence, and no other substance, with the exception of alcohol. Structured interviews of probands and family informants were used to obtain diagnostic information about probands and all their known relatives.ResultsThere was an increased morbid risk for schizophrenia in relatives of the cannabis using and non-using patient samples compared with their respective non-psychotic control samples (p = .002, p < .001 respectively). There was no significant difference in morbid risk for schizophrenia between relatives of the patients who use or do not use cannabis (p = .43).ConclusionsThe results of the current study suggest that having an increased familial morbid risk for schizophrenia may be the underlying basis for schizophrenia in cannabis users and not cannabis use by itself.